Home/Pipeline/Precision Medicine for Pain

Precision Medicine for Pain

Chronic Pain

CommercialActive

Key Facts

Indication

Chronic Pain

Phase

Commercial

Status

Active

Company

MindX Sciences

About MindX Sciences

MindX Sciences, founded in 2019 and based in Cambridge, USA, is pioneering a data-driven, biomarker-based platform for precision mental health. The company's core offering appears to be the MindX One™ blood test, a liquid biopsy designed for the objective assessment of conditions like stress, pain, and memory impairment, with the goal of guiding personalized treatment. Recent achievements include winning the Mayo ASU Healthcare Accelerator competition in 2026 and securing key patent allowances, indicating a focus on commercializing its diagnostic technology and building partnerships.

View full company profile

Therapeutic Areas

Psychiatry Pain Management Neurology

Other Chronic Pain Drugs

Drug	Company	Phase	Status
SCI-160	SciSparc	Preclinical	Active
Injectrode Platform for Chronic Pain	Neuronoff	Pre-clinical	Active
Novel PNS System	Nervonik	First-in-Human Completed	Active
Pain Pipeline	Centrexion Therapeutics	Clinical Stage	Active
High-Definition Spinal Cord Stimulation	Micro-Leads	Unknown	Active
Chronic Pain Program	Current Surgical	Research	Active
N-19a	Neurocarrus	Pre-clinical	Active
Nav1.7 ASO	Quiver Bioscience	Discovery	Active
Nav1.8 ASO	Quiver Bioscience	Discovery	Active
Dual Nav1.7/1.8 ASO	Quiver Bioscience	Discovery	Active
TMS for Chronic Pain	Magstim	Commercial/Clinical Development	Active
Platform Enhancements	Nevro	R&D	Active